Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94517ArticlesСтатьиResearch ArticleThe efficacy of αa-lipoic acid in diabetic polyneuropathyЭффективность a-липоевой кислоты при диабетической полинейропатииKhramilinV. NХрамилинВладимир Николаевич

канд. мед. наук, доц. каф. эндокринологии и диабетологии ФДПО ГБОУ ВПО РНИМУ им.Н.И.Пирогова

Khramilin_RGMU@mail.ruAndreevaV. AАндрееваВалерия Александровна

аспирант каф. эндокринологии и диабетологии ФДПО ГБОУ ВПО РНИМУ им.Н.И.Пирогова

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian FederationГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России15092015179VOL 17, NO9 (2015)ТОМ 17, №9 (2015)14414828122021Copyright ©; 2015, Consilium MedicumCopyright ©; 2015, ООО "Консилиум Медикум"2015Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94517

Diabetic polyneuropathy (DN) is a serious complication of diabetes. The aim of this review is to assess the efficacy and safety of α-lipoic acid (ALA, thioctic acid) in treatment of DN. ALA is an effective and safe treatment of DN, associated with strong and rapid antinociceptive action with delayed pathogenetic effects. In clinical practice, ALA can be used as a treatment of choice in patients with semeiotic DN associated with light and moderate sensorial deficit, as well as in case of combination of DN and the autonomic nervous system disorders.

Диабетическая полинейропатия (ДПН) является серьезным осложнением сахарного диабета. Целью данного обзора является оценка эффективности и безопасности a-липоевой кислоты (AЛК, тиоктовой кислоты) в лечении ДПН. АЛК является эффективным средством лечения ДПН, сочетая выраженное и быстрое антиноцицептивное действие с отсроченными патогенетическими эффектами. В клинической практике АЛК может быть препаратом выбора у больных с симптомной ДПН в сочетании с легким и умеренным сенсорным дефицитом, а также при сочетании ДПН с поражением вегетативной нервной системы.

diabetes mellitusdiabetic polyneuropathya-lipoic acidthioctic acidсахарный диабетдиабетическая полинейропатияa-липоевая кислотатиоктовая кислотаБреговский В.Б., Посохина О.В., Карпова И.А. Предикторы эффективности лечения диабетической полинейропатии нижних конечностей альфа - липоевой кислотой. Терапевт. архив. 2005; 10: 15-9.Храмилин В.Н., Андреева В.А., Демидова И.Ю. Комбинированная терапия болевой диабетической полинейропатии: результаты пилотного исследования. Фарматека. 2014; 16: 48-53.Храмилин В.Н., Демидова И.Ю., Игнатова О.Ю. Оценка эффективности различных режимов пероральной терапии альфа - липоевой кислотой болевой формы диабетической периферической полинейропатии. Сахарный диабет. 2010; 2: 3-7.Ametov A, Barinov A, O’Brien P et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha lipoic acid. The SYDNEY Trial. Diabetes Care 2003; 26: 770-6.Androne L, Gavan N.A, Veresiu I.A, Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000; 14: 327-30.Antonoglou C, Papanas N, Maltezos E. Lipid - lowering therapy in the diabetic foot: seeing the whole iceberg and not just the tip. Curr Vasc Pharmacol 2012. [Epub ahead of print].Available from: http://pubchem.ncbi.nlm. nih.gov/summary/summary.cgi?cid=6112Available from: http://toxnet.nlm.nih. gov/cgi-bin/sis/search2/r?dbs+hsdb:@term +@rn+@rel+1077-28-7Bansal D, Badhan Y, Gudala K, Schifano F. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J 2013; 37: 375-84.Barbiroli B, Medori R, Tritschler H.J, Iotti S. Thioctic acid stimulates muscle ATP production in patients with type-2-diabetes and diabetic polyneuropathy. Diabetes Stoffwechsel 1996; 5 (Suppl. 3): 71-6.Bierhaus A, Chevion S, Chevion M et al. Advanced glycation end productinduced activation of NF-kB is suppressed by alpha - lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-90.Borcea V, Nourooz-Zadeh J, Wolff S.P et al. Alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med 1999; 26: 1495-500.Boulton A.J, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev 2013; 29: 327-33.Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009; 32: 1256-60.Callaghan B.C, Little A.A, Feldman E.L, Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6: CD007543.Cameron N.E, Jack A.M, Cotter M.A. Effect of alpha - lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001; 31: 125-35.Carlson D.A, Smith A.R, Fischer S.J et al. The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects. Altern Med Rev 2007; 12: 343-51.Coppey L.J, Gellett J.S, Davidson E.P et al. Effect of antioxidant treatment of streptozotocin - induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-37.Coppini D.V, Bowtell P.A, Weng C et al. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000;53:519-23.Davis T.M, Yeap B.B, Davis W.A, Bruce D.G. Lipid - lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008; 51: 562-6.Evans J.L, Goldfine I.D. Alpha - lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000; 2: 401-13.Ewing D.J, Martyn C.N, Young R.J, Clarke B.F. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491-8.Forsblom C.M, Sane T, Groop P.H et al. Risk factors for mortality in Type II (non - insulin - dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998; 4: 1253-62.Galer B.S, Gianas A, Jensen M.P. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-8.Garrett N.E, Malcangio M, Dewhurst M, Tomlinson D.R. Alpha-Lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neurosci Lett 1997; 222: 191-4.Haak E, Usadel K.H, Kusterer K et al. Effects of alpha - lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000; 108: 168-74.Haak E.S, Usadel K.H, Kohleisen M et al. The effect of alpha - lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res 1999; 58: 28-34.Han T, Bai J, Liu W, Hu Y. A systematic review and meta - analysis of alpha - lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012; 167: 465-71.Heitzer T, Finckh B, Albers S et al. Beneficial effects of alpha - lipoic acid and ascorbic acid on endothelium - dependent, nitric oxide - mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001; 31: 53-61.Hoffman M, Zimmer G. Lipoate prevention of diabetic microangiopathy. In: Fuchs J, Packer L, Zimmer G, editors. Lipoic acid in health and disease. New York: Marcel Decker, 1997; p. 168-74.Hofmann M.A, Schiekofer S, Isermann B et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative - stress sensitive transcription factor NF-kappa B. Diabetologia 1999; 42: 222-32.Hofmann M.A, Schiekofer S, Kanitz M et al. Insufficient glycemic control increases nuclear factor - kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998; 21: 1310-6.Hurdag C, Ozkara H, Citci S et al. The effects of alpha - lipoic acid on nitric oxide synthetase dispersion in penile function in streptozotocin - induced diabetic rats. Int J Tissue React 2005; 27: 145-50.Jacob S, Henriksen E.J, Tritschler H.J et al. Improvement of insulin - stimulated glucose - disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes 1996; 104: 284-8.Jacob S, Rett K, Henriksen E.J, Haring H.U. Thioctic acid - effects on insulin sensitivity and glucose - metabolism. Biofactors 1999; 10: 169-74.Keegan A, Cotter M.A, Cameron N.E. Corpus cavernosum dysfunction in diabetic rats: effects of combined alphalipoic acid and gamma - linolenic acid treatment. Diabetes Metab Res Rev 2001; 17: 380-6.McIlduff C.E, Rutkove S.B. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic olyneuropathy. Ther Clin Risk Manag 2011; 7: 377-85.Mijnhout G.S, Kollen B.J, Alkhalaf A et al. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta - analysis of randomized controlled trials. Int J Endocrinol 2012; 2012: 456279.Mitkov M.D, Aleksandrova I.Y, Orbetzova M.M. Effect of transdermal testosterone or alpha - lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2013; 55: 55-63.Mitsui Y, Schmelzer J.D, Zollman P.J et al. Alpha - lipoic acid provides neuroprotection from ischemiareperfusion injury of peripheral nerve. J Neurol Sci 1999; 163: 11-16.Nagamatsu M, Nickander K.K, Schmelzer J.D et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-7.Nickander K.K, Mc Phee B.R, Low P.A, Tritschler H. Alpha - lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 1996; 21: 631-9.Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. Acta Clin Belg 2007; 62: 230-8.Papanas N, Vinik A.I, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011; 7: 682-90.Papanas N, Ziegler D. Efficacy of a - lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014; 15 (18): 2721-31.Rajamani K, Colman P.G, Li L.P et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-8.Rathmann W, Haastert B, Delling B et al. Postmarketing surveillance of adverse drug reactions: a correlational study approach usingmultiple data sources. Pharmacoepidemiol Drug Saf 1998; 7: 51-7.Reljanovic M, Reichel C, Rett K et al. Treatment of diabetic peripheral neuropathy with the antioxidant thioctic acid (alpha - lipoic acid). A two - year multicenter randomized double blind placebo controlled trial (ALADIN II). Free Rad Res 1999; 31: 171-9.Resnick H.E, Vinik A.I, Schwartz A.V et al. Independent effects of peripheral nerve dysfunction on lower - extremity physical function in old age. The Women’s Health and Aging Study. Diabetes Care 2000; 23: 1642-7.Ruessmann H.J. German Society of out patient diabetes centres AND (Arbeitsgemeinschaft niedergelassener diabetologisch ta¨tiger Arzte e.V.). Switching from pathogenetic treatment with alpha - lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real - world study in outpatients. J Diabetes Complications 2009; 23: 174-7.Ruhnau K-J, Meissner H.P, Finn J.R et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alphalipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999; 16: 1040-3.Schemmel K.E, Padiyara R.S, D’Souza J.J. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 2010; 24: 354-60.Snedecor S.J, Sudharshan L, Cappelleri J.C et al. Systematic review and meta - analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 2014; 14: 167-84.Sola S, Mir M.Q, Cheema F.A et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the irbesartan and lipoic acid in endothelial dysfunction (ISLAND) study. Circulation 2005; 111: 343-8.Spallone V, Ziegler D, Freeman R et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27: 639-53Stevens M.J, Obrosova I, Cao X et al. Effects of D.L-alpha - lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006-15.Teichert J, Hermann R, Ruus P, Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha - lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol 2003; 43: 1257-67.Teichert J, Tuemmers T, Achenbach H et al. Pharmacokinetics of alpha - lipoic acid in subjects with severe kidney damage and end - stage renal disease. J Clin Pharmacol 2005; 45: 313-28.Tesfaye S, Boulton A.J, Dyck P.J et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-93.Tesfaye S, Chaturvedi N, Eaton S.E, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-50.Tiaka E.K, Papanas N, Manolakis A.C, Maltezos E. The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers. Int J Burns Trauma 2011; 1: 68-76.Várkonyi T, Putz Z, Keresztes K et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des 2013; 19: 4981-5007.Vincent A.M, Hayes J.M, Mc Lean L.L et al. Dyslipidemia - induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009; 58: 2376-85.Vinik A.I, Maser R.E, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care 2010; 33: 1688-90.Vinik A.I, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-97.Ziegler D, Ametov A, Barinov A et al. Oral treatment with alpha - lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-70.Ziegler D, Hanefeld M, Ruhnau K.J et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha - lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-33.Ziegler D, Hanefeld M, Ruhnau K.J et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha - lipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999; 22: 1296-301.Ziegler D, Low P.A, Litchy W.J et al. Efficacy and safety of antioxidant treatment with alpha - lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34: 2054-60.Ziegler D, Nowak H, Kempler P et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha - lipoic acid: a meta - analysis. Diabet Med 2004; 21: 114-21.Ziegler D, Rathmann W, Dickhaus T, KORA Study Group. Prevalence of polyneuropathy in pre - diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31: 464-9.Ziegler D, Schatz H, Conrad F et al. Effects of treatment with the antioxidant alpha - lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997; 20: 369-73.Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008; 24 (Suppl. 1): S52-7.Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004; 3: 173-89.